Gefapixant
Gefapixant
Chemical compound
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough.[1] It acts as an antagonist of the P2RX3 receptor.[2][3][4]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Lyfnua |
Other names | MK-7264 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.258.106 |
Chemical and physical data | |
Formula | C14H19N5O4S |
Molar mass | 353.40 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
It was approved for medical use in the European Union in September 2023.[1]
Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.[1]
Names
It was named in honour of Geoff Burnstock.[5]
- "Lyfnua EPAR". European Medicines Agency. 29 September 2023. Retrieved 5 October 2023.
- Richards D, Gever JR, Ford AP, Fountain SJ (July 2019). "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology. 176 (13): 2279–2291. doi:10.1111/bph.14677. PMC 6555852. PMID 30927255.
- Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents. 29 (12): 943–963. doi:10.1080/13543776.2019.1693542. hdl:11581/435751. PMID 31726893. S2CID 208037373.
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |